Project Grant R01AG099125
- The National Institute on Aging awarded the National Opinion Research Center $2.489 million on September 1, 2026, under the Aging Research program (CFDA 93.866) for a project grant (R01AG102939) titled "NSHAP Caregiver Study — Networks, Experiences, and Health Outcomes Across the Life Course." The recipient will conduct a comprehensive follow-up study of caregivers participating in Round 5 of the National Social Life, Health, and Aging Project. The project will collect original data...
- The National Institute on Aging awarded New York University $3.053 million on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal research on caregiving networks and their consequences among adults ages 85 and older. The award funds the ARIC CARES study, embedded within the Atherosclerosis Risk in Communities Study cohort. The research will characterize care ecosystems and relational coordination (teamwork) among family caregivers, paid caregivers, and...
- The National Institute on Aging awarded Visiting Nurse Service of New York $1,271,742 on September 15, 2025, under the Aging Research program (CFDA 93.866) to conduct a Stage II trial expanding the Virtual Caregiver Coach for You (ViCCY) intervention to caregivers of home health care patients with concurrent heart failure and cognitive impairment. The project enrolls 254 caregivers supporting patients with heart failure and cognitive impairment from home health care in New York City, plus at...
- The National Institute on Aging awarded the University of Rochester $188,445 on August 5, 2026, under the Aging Research program (CFDA 93.866) to conduct a randomized controlled trial evaluating dyadic life review therapy for distressed caregivers of older patients with Alzheimer's disease and related dementias and advanced cancer. The study will enroll 60 dyads of patients aged 65 and older with clinical impressions of AD/ADRD (including mild cognitive impairment) and stage III or IV cancer,...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging awarded The Washington University $651,035 on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop predictive markers for amyloid-related imaging abnormalities in Alzheimer's disease patients treated with amyloid-targeted therapies. The project integrates data from two complementary cohorts: the Dominantly Inherited Alzheimer Network Trials Unit, the longest-treated anti-amyloid cohort with harmonized clinical, imaging, and biomarker data and...
- The National Institute on Aging awarded The Washington University $406,707 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a national longitudinal study examining whether integrated dual-eligible special needs plans improve health outcomes for adults with intellectual disabilities and dementia who are dually enrolled in Medicare and Medicaid. The study addresses the absence of national research on dementia care access, quality, and outcomes among...
- The National Institute on Aging awarded Wake Forest University Health Sciences $633,510 on September 1, 2026, under the Aging Research program (CFDA 93.866) to examine the impact of home-based medical care and telemedicine use on dementia care outcomes among Medicare enrollees with Alzheimer's disease and related dementias. The project will study home-based medical care delivery—house calls by physicians and advanced care providers—and telemedicine use among persons living with Alzheimer's...
- The National Institute on Aging awarded The Washington University $427,625 under the Aging Research program (CFDA 93.866) on February 1, 2026, to conduct a two-year study examining age differences in the acquisition and retention of flexible navigation behaviors in novel environments. The research tests a model that attributes age-related navigation deficits to limitations in processing speed, attentional control, and associative processes. The study involves study-test trials conducted across...
- The National Institute on Aging awarded the University of Pennsylvania $198,164 on October 29, 2025, under the Aging Research program (CFDA 93.866) to support an Individual National Research Service Award (NRSA) for predoctoral research training focused on dementia-friendly hospitalization practices and family caregiver inclusion. The award funds research training that enables the applicant, an acute care nurse and clinical nurse specialist, to develop competence in understanding the care of...
The National Institute on Aging awarded The Washington University $746,009 on August 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a Stage III randomized controlled trial of Peer Caregiver Navigation (PCN), a paraprofessional peer-delivered intervention designed to reduce anxiety symptoms, depressive symptoms, and perceived stress among family caregivers of persons living with Alzheimer's disease. The study will enroll 466 Alzheimer's disease caregivers randomly assigned to one of two groups: usual care delivered by dementia care clinicians and community service providers, or usual care plus the PCN intervention. PCN delivers 1:1 paraprofessional peer coaching focused on coping skills, psychoeducation, and peer support. The trial will test causal hypotheses linking the intervention to mechanisms of change including self-efficacy and coping to explain improvement in caregiver outcomes. The research will also examine constraints and facilitators to implementation and sustainability among a subsample of intervention participants and 30 key informants from clinics and community-based organizations. Prior feasibility and pilot work with cancer and dementia caregivers demonstrated expected measurement change in anxiety symptoms, depression, self-efficacy, and coping. Performance occurs at The Washington University's Office of Sponsored Research Services in St. Louis, Missouri. The period of performance extends from August 1, 2026, through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $117.1k | 8/14/26 | ||
| Not listed | $628.9k | 7/29/26 |